查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869623

多形性膠質母細胞瘤治療市場規模、佔有率和趨勢分析報告：按療法、最終用途、地區和細分市場預測（2025-2033 年）

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多形性膠質母細胞瘤治療市場摘要

2024年全球多形性膠質母細胞瘤治療市場規模估計為37.2億美元，預計2033年將達到78.7億美元。

預計從 2025 年到 2033 年，該行業將以 8.68% 的複合年成長率成長。多形性膠質母細胞瘤 (GBM) 的盛行率不斷上升及其帶來的重大臨床負擔是 GBM 治療行業的關鍵促進因素。

由於診斷能力的提高和病例數量的大幅增加，膠質母細胞瘤（GBM）的發生率在全球範圍內持續上升。尤其令人擔憂的是，隨著老齡化的成長，GBM在高齡化社會中的影響日益加劇。隨著全球老年人口的持續成長，預計GBM病例數將繼續增加，這將給醫療保健系統帶來更大的壓力，並凸顯出對更有效治療方法的迫切需求。

來自世界各地醫療機構的數據凸顯了膠質母細胞瘤（GBM）日益加重的臨床負擔。例如，新加坡百匯癌症中心在2024年12月報告稱，該國每年新增約100例GBM病例，凸顯了該國先進的神經腫瘤基礎設施所面臨的巨大壓力。 GBM患者通常需要接受強化、多學科的治療，通常包括放射線治療以及術後合併放療和化療。然而，GBM復發率很高，通常在數月內出現，凸顯了現有治療方法的限制。該中心的報告強調了持續推進個人化醫療的重要性，特別是透過整合基因組學和免疫療法，以應對GBM治療的複雜性。

此外，先進技術在神經外科領域的應用正在改善膠質母細胞瘤（GBM）患者的治療效果，並進一步擴大新興市場患者的治療機會。例如，研究表明，術中磁振造影（Io-MRI）透過提高腫瘤切除率顯著提升了手術成功率。 2024年發表於《神經腫瘤學雜誌》（Journal of Neuro-Oncology）的一項研究證實，Io-MRI引導下的手術將腫瘤完全切除率從33.6%提高到49.6%，降低了患者復發率，並延長了無惡化生存期。

該療法的全球推廣也得益於醫療資源的改善和有利的醫保報銷環境。在多個國家，醫療系統已將TTF納入醫療保險範圍，從而消除了符合條件的患者的經濟障礙。據Novocure公司稱，截至2024年底，全球已有超過4000名患者使用其Optune Geo TTF系統，其中美國、德國、法國和日本的患者數量尤為突出。不斷成長的患者群體表明，無論是在已開發醫療市場還是新興醫療市場，人們對TTF療法的臨床信心和接受度都在不斷提高。此外，該療法的成功也推動了技術的進一步改進和對膠質母細胞瘤（GBM）以外的新適應症研究。這些趨勢共同重塑了治療格局，並將TTF定位為未來GBM治療方案的關鍵組成部分。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 多形性膠質母細胞瘤治療市場的變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

第4章 多形性膠質母細胞瘤治療市場：依療法分類的業務分析

  • 按療法分類的市場佔有率，2024 年和 2033 年
  • 治療細分儀表板
  • 按療法分類的市場規模、預測和趨勢分析，2021-2033年
  • 外科手術
  • 放射治療
  • 化療
  • 標靶治療（Bevacizumab）

5. 多形性膠質母細胞瘤治療市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2024 年和 2033 年
  • 最終用戶細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析，2021-2033年
  • 醫院
  • 診所/門診中心
  • 門診手術中心
  • 其他

第6章 多形性膠質母細胞瘤治療市場：各國估算與趨勢分析

  • 2024 年及 2033 年各國市場
  • 各國市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • Merck &Co., Inc.
    • Teva Pharmaceutical
    • Sun Pharma
    • Amneal Pharmaceuticals
    • F. Hoffmann-La Roche Ltd.
    • Amgen, Inc.
    • Pfizer Inc.
    • Arbor Pharmaceuticals（Azurity）
    • Karyopharm Therapeutics, Inc.
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country's advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy's growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Lomustine
    • Carmustine Wafers
    • Other
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics / Outpatient Centers
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Temozolomide
      • 4.6.2.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Lomustine
      • 4.6.3.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Carmustine Wafers
      • 4.6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Other
      • 4.6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy (Bevacizumab)
    • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End-Use Business Analysis

  • 5.1. End-Use Market Share, 2024 & 2033
  • 5.2. End-Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Clinics / Outpatient Centers
    • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Ambulatory Surgical Centers
    • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Countries Estimates & Trend Analysis

  • 6.1. Country Market Share Analysis, 2024 & 2033
  • 6.2. Country Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
    • 6.3.1. U.S.
      • 6.3.1.1. Key Country Dynamics
      • 6.3.1.2. Target Disease Prevalence
      • 6.3.1.3. Regulatory Framework
      • 6.3.1.4. Reimbursement Framework
      • 6.3.1.5. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Framework
      • 6.3.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Framework
      • 6.3.3.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. UK Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Framework
      • 6.4.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Framework
      • 6.4.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Framework
      • 6.4.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Reimbursement Framework
      • 6.4.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Target Disease Prevalence
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Reimbursement Framework
      • 6.4.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Middle East and Africa
    • 6.7.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Target Disease Prevalence
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Reimbursement Framework
      • 6.7.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Target Disease Prevalence
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Reimbursement Framework
      • 6.7.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Merck & Co., Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Teva Pharmaceutical
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sun Pharma
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Amneal Pharmaceuticals
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amgen, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Pfizer Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Arbor Pharmaceuticals (Azurity)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Karyopharm Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5. Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 6. North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8. North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 9. U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10. U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 11. Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12. Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 13. Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14. Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 15. Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17. Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 18. UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19. UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 20. Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21. Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 22. France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23. France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 24. Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25. Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 26. Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27. Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 28. Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29. Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 30. Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31. Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 32. Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33. Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD
  • Table 36. Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 37. Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38. Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 39. China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40. China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 41. India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42. India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 43. Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44. Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 45. South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46. South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 47. Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48. Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 49. Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51. Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 52. Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53. Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 54. Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55. Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 59. South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60. South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 63. UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64. UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 65. Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66. Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Glioblastoma multiforme treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end-use segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Pharmaceutical market value, 2024 (USD billion)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Porter's five force analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 Glioblastoma multiforme treatment market: By treatment: Key takeaways
  • Fig. 16 Glioblastoma multiforme treatment market, By treatment: market share, 2024 & 2033
  • Fig. 17 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 18 Radiation therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 20 Temozolomide market, 2021 - 2033 (USD Million)
  • Fig. 21 Lomustine settings market, 2021 - 2033 (USD Million)
  • Fig. 22 Carmustine wafers market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 25 Tumor treating field (TTF) therapy market, 2021 - 2033 (USD Million)
  • Fig. 26 Glioblastoma multiforme treatment market: By End Use key takeaways
  • Fig. 27 Glioblastoma multiforme treatment market, By End Use: market share, 2024 & 2033
  • Fig. 28 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 29 Clinics / Outpatient Centers market, 2021 - 2033 (USD Million)
  • Fig. 30 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 31 Others market, 2021 - 2033 (USD Million)
  • Fig. 32 Glioblastoma multiforme treatment market revenue, by region, 2024 & 2033 (USD Million)
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. Glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Regulatory framework
  • Fig. 43 Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Japan glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 China glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Regulatory details: China
  • Fig. 49 Exclusivity formula
  • Fig. 50 Key country dynamics
  • Fig. 51 India glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Registration details: India
  • Fig. 53 Key country dynamics
  • Fig. 54 Australia glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Contribution of PBS by disease
  • Fig. 56 Key country dynamics
  • Fig. 57 Thailand glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 South Korea glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Reimbursement scenario
  • Fig. 61 Rest of Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina regulatory details
  • Fig. 63 Reimbursement scenario in Argentina
  • Fig. 64 Rest of Latin America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 South Africa glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Regulatory framework: South Africa
  • Fig. 69 Key country dynamics
  • Fig. 70 Saudi Arabia glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia pharmaceuticals regulation details
  • Fig. 72 Key country dynamics
  • Fig. 73 UAE glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Kuwait glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Regulatory framework: Kuwait
  • Fig. 77 Rest of MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Market participant categorization
  • Fig. 79 Strategic framework